Health
DARE-19: No significant decrease in major events; dapagliflozin well tolerated in COVID-19 – Healio
The SGLT2 inhibitor dapagliflozin did not significantly reduce risk for organ failure or death or improve recovery among adults hospitalized with COVID-19 vs. placebo,…
Source/Disclosures
Source: Kosiborod M, et al. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
Disclosures:
The DARE-19 trial was funded by AstraZeneca. Kosiborod reports he received grants or advisory board, consultant or speaking fees from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk…
-
Noosa News17 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business18 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News21 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Noosa News21 hours ago‘They’re not taking the concerns of women seriously’